Biological
Ad5-nCoV vaccine clinical trials
Also written Ad5-nCoV.
- studies test it
- 12
- open now
- 0
- in phase 3
- 2
- first study started
- 2020
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2020 (7)
| Year | Studies |
|---|---|
| 2020 | 7 |
| 2021 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 6
- Phase 3
- 2
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 10
Who runs them
Industry 6 · Other 6
CanSino Biologics Inc. (5) · Fundación Huésped (2) · Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China (2) · Jiangsu Province Centers for Disease Control and Prevention (2) · NPO Petrovax (1)
Studies
Open first, then newest update. How each study uses Ad5-nCoV vaccine is read from its arms, and is right about nine times in ten.
Testing it · 12
- Phase IIB Study of Recombinant Novel Coronavirus VaccineCompletedPhase 2Fundación HuéspedNCT05293223Written as Ad5-nCov
- Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIVCompletedPhase 2Fundación HuéspedNCT05005156Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
- Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19CompletedPhase 3NPO PetrovaxNCT04540419Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and AboveCompletedPhase 3CanSino Biologics Inc.NCT04526990Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy AdultsCompletedPhase 1Institute of Biotechnology, Academy of Military Medical Sciences, PLA of ChinaNCT04552366Written as Ad5-nCoV
- A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)CompletedPhase 2Institute of Biotechnology, Academy of Military Medical Sciences, PLA of ChinaNCT04341389Written as Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)
- Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for InhalationCompletedPhase 1/2CanSino Biologics Inc.NCT04840992Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)CompletedPhase 2CanSino Biologics Inc.NCT04566770Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly AdultsCompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT04952727Written as Recombinant SARS-CoV-2 Ad5 vectored vaccine
- Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)CompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT04892459Written as Recombinant SARS-CoV-2 Ad5 vectored vaccine
- Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy AdultsCompletedPhase 1CanSino Biologics Inc.NCT04313127Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in CanadaStatus unknownPhase 1/2CanSino Biologics Inc.NCT04398147Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Given in every arm · 2 — Ad5-nCoV vaccine is usual care beside what is tested
- A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and AdolescentsTerminatedPhase 3CanSino Biologics Inc.NCT05169008Written as Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit VaccineCompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT04833101Written as recombinant Ad5 vectored COVID-19 vaccine
Codes
What other systems call Ad5-nCoV vaccine · ClinicalTrials.gg INT001303
- MeSH (NLM) C000706167Ad5-nCoV vaccineOne source NLM
- UNII (FDA) 5AHC3V2UQSAD5-NCOVConfirmed NLM, Wikidata
- Wikidata Q96695265Ad5-nCoVConfirmed NLM, Wikidata
- DrugBank DB15655One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706167 | Ad5-nCoV vaccine | One source NLM |
| UNII (FDA) | 5AHC3V2UQS | AD5-NCOV | Confirmed NLM, Wikidata |
| Wikidata | Q96695265 | Ad5-nCoV | Confirmed NLM, Wikidata |
| DrugBank | DB15655 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.